Kates R - Search Results

1

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.

Nitz U, Gluz O, Graeser M, Christgen M, Kuemmel S, Grischke EM, Braun M, Augustin D, Potenberg J, Krauss K, Schumacher C, Forstbauer H, Reimer T, Stefek A, Fischer HH, Pelz E, Zu Eulenburg C, Kates R, Wuerstlein R, Kreipe HH, Harbeck N; WSG-ADAPT investigators. Nitz U, et al. Among authors: kates r. Lancet Oncol. 2022 May;23(5):625-635. doi: 10.1016/S1470-2045(22)00159-0. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405088 Clinical Trial.

2

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: kates re. Breast Cancer Res Treat. 1999 Mar;54(2):147-57. doi: 10.1023/a:1006118828278. Breast Cancer Res Treat. 1999. PMID: 10424405

3

Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.

Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: kates r. Int J Biol Markers. 2000 Jan-Mar;15(1):79-83. doi: 10.1177/172460080001500115. Int J Biol Markers. 2000. PMID: 10763146 Free article.

4

Neural network analysis of follow-up data in primary breast cancer.

Harbeck N, Kates R, Ulm K, Graeff H, Schmitt M. Harbeck N, et al. Among authors: kates r. Int J Biol Markers. 2000 Jan-Mar;15(1):116-22. doi: 10.1177/172460080001500123. Int J Biol Markers. 2000. PMID: 10763154 Free article.

5

Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.

Harbeck N, Krüger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Jänicke F. Harbeck N, et al. Among authors: kates re. Onkologie. 2001 Jun;24(3):238-44. doi: 10.1159/000055086. Onkologie. 2001. PMID: 11455216 Review. English, German.

6

Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M. Harbeck N, et al. Among authors: kates re. Clin Cancer Res. 2001 Sep;7(9):2757-64. Clin Cancer Res. 2001. PMID: 11555589

7

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.

Harbeck N, Kates RE, Schmitt M. Harbeck N, et al. J Clin Oncol. 2002 Feb 15;20(4):1000-7. doi: 10.1200/JCO.2002.20.4.1000. J Clin Oncol. 2002. PMID: 11844823

8

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA. Harbeck N, et al. Cancer Res. 2002 Aug 15;62(16):4617-22. Cancer Res. 2002. PMID: 12183417

9

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

10

Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.

Zemzoum I, Kates RE, Ross JS, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Zemzoum I, et al. J Clin Oncol. 2003 Mar 15;21(6):1022-8. doi: 10.1200/JCO.2003.04.170. J Clin Oncol. 2003. PMID: 12637466

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

245 results

Search Page

Filters